MedTrace Logo

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

NCT02052986 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-02-03

No results posted yet for this study

Summary

The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.

Conditions

Interventions

OTHER

VASCAZEN

All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA

Sponsors & Collaborators

  • NYHQ Cardiac Health Center

    collaborator UNKNOWN

  • Pivotal Therapeutics

    collaborator UNKNOWN

  • New York Hospital Queens

    lead OTHER

Principal Investigators

  • Brian S Marino, DO · New York Hospital Queens

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052986 on ClinicalTrials.gov